- Home
- RDWR vs NUVB Comparison
RDWR vs NUVB Comparison
Compare RDWR & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- NUVB
- Stock Information
- Founded
- RDWR 1996
- NUVB 2018
- Country
- RDWR Israel
- NUVB United States
- Employees
- RDWR N/A
- NUVB N/A
- Industry
- RDWR EDP Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- RDWR Technology
- NUVB Health Care
- Exchange
- RDWR Nasdaq
- NUVB Nasdaq
- Market Cap
- RDWR 865.9M
- NUVB 959.2M
- IPO Year
- RDWR 1999
- NUVB N/A
- Fundamental
- Price
- RDWR $22.00
- NUVB $2.58
- Analyst Decision
- RDWR Hold
- NUVB Strong Buy
- Analyst Count
- RDWR 3
- NUVB 6
- Target Price
- RDWR $30.00
- NUVB $7.00
- AVG Volume (30 Days)
- RDWR 123.0K
- NUVB 2.8M
- Earning Date
- RDWR 02-12-2025
- NUVB 02-27-2025
- Dividend Yield
- RDWR N/A
- NUVB N/A
- EPS Growth
- RDWR N/A
- NUVB N/A
- EPS
- RDWR N/A
- NUVB N/A
- Revenue
- RDWR $266,880,999.00
- NUVB $2,162,000.00
- Revenue This Year
- RDWR $6.71
- NUVB N/A
- Revenue Next Year
- RDWR $6.58
- NUVB $369.72
- P/E Ratio
- RDWR N/A
- NUVB N/A
- Revenue Growth
- RDWR N/A
- NUVB N/A
- 52 Week Low
- RDWR $16.12
- NUVB $1.52
- 52 Week High
- RDWR $24.76
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- RDWR 47.36
- NUVB 45.02
- Support Level
- RDWR $20.47
- NUVB $2.47
- Resistance Level
- RDWR $22.73
- NUVB $2.77
- Average True Range (ATR)
- RDWR 0.58
- NUVB 0.23
- MACD
- RDWR 0.01
- NUVB -0.04
- Stochastic Oscillator
- RDWR 59.77
- NUVB 13.30
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. The company generates maximum revenue from the United States.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).